Baidu
map

Sci Rep:计算机辅助结节评估和风险收益(CANARY)可以促进对肺腺癌EGFR突变状态的非侵入性预测

2017-12-16 xiangting MedSci原创

结节和周围肺的定量CT分析可以非侵入性地预测EGFR突变在肺腺癌结节中的存在。

计算机辅助结节评估和风险收益(CANARY)是定量成像分析软件,用于预测肺腺癌患者的组织病理学分类和治疗后的无病生存率。CANARY通过九个颜色编码基于纹理示例的分布来表征结节。这项研究假设对肿瘤和无肿瘤周围肺的定量计算机断层扫描(CT)分析有助于肺腺癌中临床相关突变的非侵入性鉴别。

研究对象为2006 - 2010年间手术切除的118个肺腺癌肺结节,对靶向突变(50-gene-panel)进行综合性分析,对术前(≤3个月)高分辨率CT(HRCT)进行CANARY分析。使用逐步变量选择的logistic回归来确定突变的预测因子。在118个结节中的106个中鉴定了140个突变。TP53(n = 48),KRAS(n = 47)和EGFR(n = 15)是最常见的。Y(黄色)和G(绿色)样本的组合,周围肺纤维化和吸烟状态是EGFR突变的最佳鉴别因子(AUC分别为 0.77和0.87)。基于CANARY特征,表达TP53的EGFR突变体(n = 5)均预后不好。没有定量的特征与KRAS突变显著相关。

这项探索性分析表明,结节和周围肺的定量CT分析可以非侵入性地预测EGFR突变在肺腺癌结节中的存在。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1716383, encodeId=a9f61e16383d8, content=<a href='/topic/show?id=d68d911542f' target=_blank style='color:#2F92EE;'>#计算机#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91154, encryptionId=d68d911542f, topicName=计算机)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=def632217870, createdName=bioon14, createdTime=Wed Feb 14 04:16:00 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633433, encodeId=94f016334331e, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Thu Sep 06 14:16:00 CST 2018, time=2018-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034670, encodeId=dbed20346e0a9, content=<a href='/topic/show?id=cf91992e053' target=_blank style='color:#2F92EE;'>#非侵入性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99270, encryptionId=cf91992e053, topicName=非侵入性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Thu May 03 13:16:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028765, encodeId=9ed62028e6596, content=<a href='/topic/show?id=b1e1269e5c6' target=_blank style='color:#2F92EE;'>#侵入性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26975, encryptionId=b1e1269e5c6, topicName=侵入性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Mar 20 16:16:00 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534359, encodeId=1490153435987, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Mon Dec 18 06:16:00 CST 2017, time=2017-12-18, status=1, ipAttribution=)]
    2018-02-14 bioon14
  2. [GetPortalCommentsPageByObjectIdResponse(id=1716383, encodeId=a9f61e16383d8, content=<a href='/topic/show?id=d68d911542f' target=_blank style='color:#2F92EE;'>#计算机#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91154, encryptionId=d68d911542f, topicName=计算机)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=def632217870, createdName=bioon14, createdTime=Wed Feb 14 04:16:00 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633433, encodeId=94f016334331e, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Thu Sep 06 14:16:00 CST 2018, time=2018-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034670, encodeId=dbed20346e0a9, content=<a href='/topic/show?id=cf91992e053' target=_blank style='color:#2F92EE;'>#非侵入性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99270, encryptionId=cf91992e053, topicName=非侵入性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Thu May 03 13:16:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028765, encodeId=9ed62028e6596, content=<a href='/topic/show?id=b1e1269e5c6' target=_blank style='color:#2F92EE;'>#侵入性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26975, encryptionId=b1e1269e5c6, topicName=侵入性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Mar 20 16:16:00 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534359, encodeId=1490153435987, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Mon Dec 18 06:16:00 CST 2017, time=2017-12-18, status=1, ipAttribution=)]
    2018-09-06 AspirantSuo
  3. [GetPortalCommentsPageByObjectIdResponse(id=1716383, encodeId=a9f61e16383d8, content=<a href='/topic/show?id=d68d911542f' target=_blank style='color:#2F92EE;'>#计算机#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91154, encryptionId=d68d911542f, topicName=计算机)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=def632217870, createdName=bioon14, createdTime=Wed Feb 14 04:16:00 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633433, encodeId=94f016334331e, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Thu Sep 06 14:16:00 CST 2018, time=2018-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034670, encodeId=dbed20346e0a9, content=<a href='/topic/show?id=cf91992e053' target=_blank style='color:#2F92EE;'>#非侵入性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99270, encryptionId=cf91992e053, topicName=非侵入性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Thu May 03 13:16:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028765, encodeId=9ed62028e6596, content=<a href='/topic/show?id=b1e1269e5c6' target=_blank style='color:#2F92EE;'>#侵入性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26975, encryptionId=b1e1269e5c6, topicName=侵入性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Mar 20 16:16:00 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534359, encodeId=1490153435987, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Mon Dec 18 06:16:00 CST 2017, time=2017-12-18, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1716383, encodeId=a9f61e16383d8, content=<a href='/topic/show?id=d68d911542f' target=_blank style='color:#2F92EE;'>#计算机#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91154, encryptionId=d68d911542f, topicName=计算机)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=def632217870, createdName=bioon14, createdTime=Wed Feb 14 04:16:00 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633433, encodeId=94f016334331e, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Thu Sep 06 14:16:00 CST 2018, time=2018-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034670, encodeId=dbed20346e0a9, content=<a href='/topic/show?id=cf91992e053' target=_blank style='color:#2F92EE;'>#非侵入性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99270, encryptionId=cf91992e053, topicName=非侵入性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Thu May 03 13:16:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028765, encodeId=9ed62028e6596, content=<a href='/topic/show?id=b1e1269e5c6' target=_blank style='color:#2F92EE;'>#侵入性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26975, encryptionId=b1e1269e5c6, topicName=侵入性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Mar 20 16:16:00 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534359, encodeId=1490153435987, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Mon Dec 18 06:16:00 CST 2017, time=2017-12-18, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1716383, encodeId=a9f61e16383d8, content=<a href='/topic/show?id=d68d911542f' target=_blank style='color:#2F92EE;'>#计算机#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91154, encryptionId=d68d911542f, topicName=计算机)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=def632217870, createdName=bioon14, createdTime=Wed Feb 14 04:16:00 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633433, encodeId=94f016334331e, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Thu Sep 06 14:16:00 CST 2018, time=2018-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034670, encodeId=dbed20346e0a9, content=<a href='/topic/show?id=cf91992e053' target=_blank style='color:#2F92EE;'>#非侵入性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99270, encryptionId=cf91992e053, topicName=非侵入性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Thu May 03 13:16:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028765, encodeId=9ed62028e6596, content=<a href='/topic/show?id=b1e1269e5c6' target=_blank style='color:#2F92EE;'>#侵入性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26975, encryptionId=b1e1269e5c6, topicName=侵入性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Mar 20 16:16:00 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534359, encodeId=1490153435987, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Mon Dec 18 06:16:00 CST 2017, time=2017-12-18, status=1, ipAttribution=)]
    2017-12-18 liuyiping

相关资讯

Eur Radiol:胸部CT读片,有啥好办法提高检出以磨玻璃影为主肺癌的正确率呢?

本研究旨在评估CT时间剪影(TS)方法在检出以磨玻璃影为主肺癌(LC-pGGO)的价值,并将结果发表在Eur Radiol上。

胸外专题:机器人辅助肺癌支气管袖式切除术

支气管袖式切除术是治疗中央型肺癌的最佳手术方式,但多数需要开胸手术才能完成。本文探讨机器人辅助肺癌支气管袖式切除术的可行性和手术方案。

早期肺癌外科治疗策略

随着胸部CT肺癌筛查项目的开展和百姓健康体检意识的增强,大量的低剂量螺旋CT被应用于肺癌筛查项目中,更多的肺内小结节患者走进我们的视野。这虽然可以使更多的早期肺癌患者通过微创外科手术得以根治治疗,但目前存在的过度诊断和过度治疗引起了胸外科学界和肿瘤学界的关注与担忧。

病例分享:“峰回路转”的1例肺癌患者治疗

患者女性,46岁,主因“咳嗽伴右侧肋部疼痛2月余”于2013年1月14日就诊我科。

PLos One:使用顺铂 vs.卡铂治疗肺癌的血栓栓塞风险比较

肺癌患者中卡铂相关性TEEs的发生率高,顺铂和卡铂组间出现TEEs的风险没有显著差异。

重复 Cell:肺癌患者的希望!两药联合应用可能会增加肺癌患者的免疫治疗反应

约翰霍普金斯Kimmel癌症中心的研究人员和同事们已经确定了一种新型的药物联合疗法,可以使非小细胞肺癌更好地应对免疫治疗。这些所谓的表观遗传治疗药物一起使用,在人癌细胞系和小鼠中实现了强大的抗肿瘤应答。

Baidu
map
Baidu
map
Baidu
map